The life sciences team at Optum™ will contribute a significant volume of scientific content to the ISPOR 16th Annual European Congress. Our industry-renowned experts will explore a wide variety of topics relevant to today’s evolving economic, regulatory and health care landscapes.

Our more than 40 scientific contributions to this year's European Congress will include forums, short courses, posters, podium presentations, issue panels and workshops; see the full schedule below.

Jump to:
• Saturday, 2 Nov
• Sunday, 3 Nov
• Monday, 4 Nov
• Tuesday, 5 Nov
• Wednesday, 6 Nov

---

Contributions

Saturday, 2 Nov

Short course: 9:00–13:00

Add to Outlook

INTRODUCTION TO DATABASE ANALYSIS OF OBSERVATIONAL STUDIES OF TREATMENT EFFECTS

Faculty: Bradley C. Martin, PharmD, RPh, PhD, Professor and Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
Linus Jönsson, PhD, MD, MSc, Executive VP & Senior Scientist, Optum and Karolinska Institutet, Stockholm, Sweden.

Course Description: Retrospective studies require strong principles of epidemiologic study design and complex analytical methods to adjust for bias and confounding. This course will provide an overview of the structures of commonly encountered retrospective data sources with a focus on large administrative data and highlight design and measurement issues investigators face when developing a protocol using retrospective observational data. Approaches to measure and control for patient mix including patient comorbidity and the use of restriction and stratification will be presented. Linear multivariable regression, logistic regression and propensity scoring analytic techniques will be presented and include examples and SAS code that can later be used by participants. This course is an introductory course designed to prepare participants to take intermediate and advanced observational research course.

Short course: 14:00–18:00

Add to Outlook

USE OF PROPENSITY SCORES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS

Faculty: John Seeger, PharmD, DrPH, Lecturer in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School/Brigham and Women's Hospital, Boston, MA, USA.

Course Description: In observational research, issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. No control over the treatment assignment and the lack of balance in the covariates between the treatment and control groups can produce confounded estimates of treatment effect. Faculty will explain how propensity scores can be used to mitigate confounding through standard observational approaches (restriction, stratification, modeling, matching, regression, or weighting). The advantages and disadvantages of standard adjustment relative to propensity score-based methods will be discussed. Details of propensity score methodology (variable selection, use and diagnostics) and issues surrounding validation will also be discussed.

Sunday, 3 Nov

Short course: 13:00–17:00

Add to Outlook

ADVANCED ECONOMETRIC METHODS FOR ESTIMATING TREATMENT EFFECTS IN OBSERVATIONAL STUDIES

Faculty: William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA.

Course Description: Administrative claims and electronic health record databases provide an opportunity to examine retrospectively the effects of drug use on clinical and economic outcomes in real world settings. This course will describe analytic techniques for estimation of treatment effects and statistical properties of estimators including bias, efficiency and mean square error. It will briefly review the assumptions underlying ordinary least squares regression (OLS) and the implications of violations (e.g., heteroscedasticity, multicollinearity, autocorrelation). Particular emphasis will be placed on model specification including structural equation models and alternative statistical estimators when OLS is not the appropriate methodology. Maximum likelihood estimation will be discussed along with the concepts of endogeneity and instrumental variables estimation.

Monday, 4 Nov

Forum: 18:00–19:00

Add to Outlook

MEET THE EDITORS OF VALUES IN HEALTH
This forum will provide attendees with the opportunity to meet with the editors of Value in Health.  Session topics include: What makes a great paper?  How will my paper be reviewed?  How can I volunteer to be a reviewer for Value in Health?  The editors will also be on hand to answer any other questions you may have about publishing in Value in Health. Presented by the Co-Editors-in-Chief of Value in Health.

Moderators/Speakers: Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research Department, University of Maryland, Baltimore, MD, USA.

Speakers: Several Co-Editors of Value in Health will also participate in the discussion.

Poster session I: 8:45–14:15

Add to Outlook

PIN37 BURDEN OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN SWEDEN
Nilsson J¹; Cassel T², Lindquist L^3
1Optum, Stockholm, Sweden, ²Sanofi Pasteur MSD Sweden, Solna, Sweden, ³Karolinska Institute, Solna, Sweden

PIN58 DIRECT MEDICAL COSTS AND HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH SELECTED ANTIBIOTIC TREATMENT PATHWAYS IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN US
Fan W¹ ; LaPensee K¹; Mao J²; Iorga S², Lodise TP^3
1The Medicines Company, Parsippany, NJ, USA, ²Optum, Eden Prairie, MN, USA, ³Albany College of Pharmacy and Health Sciences, Albany, NY, USA

PIN85 DIFFERENT DISCOUNTING APPROACHES AND THEIR IMPACT IN ECONOMIC EVALUATION: A PRACTICAL EXAMPLE USING HEPATITIS B VACCINATION
Cure S¹; Bianic F²; Nandini Kahol D¹, Davie A^1
1Optum, Uxbridge, United Kingdom, ²Optum, Nanterre, France

PIN96 LONG-TERM OUTCOMES OF SOFOSBUVIR (SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (CHC) PATIENTS
Cure S¹; Guerra I¹, Dusheiko G^2
1Optum, Uxbridge, United Kingdom, ²Royal free hospital, London, United Kingdom

PIN104 COST-UTILITY ANALYSIS OF POSACONAZOLE VS. FLUCONAZOLE FOR PREVENTION OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN SWEDEN
Lundberg JG¹; Jensen AV¹; Bjorkholm M²; Hoglund M³, Akerborg O^4
1MSD, Sollentuna, Sweden, ²Karolinska University Hospital Solna, Stockholm, Sweden, ³University Hospital, Uppsala, Uppsala, Sweden, ⁴Optum, Stockholm, Sweden

PSY28 HEALTH AND SOCIAL CARE RESOURCE USE BY INDIVIDUALS WITH FRAGILE X SYNDROME: RESULTS OF TWO DELPHI PANELS
Barry SJ¹; London P²; Bostock T¹; Adlard N³; Lakhdari K⁴; Aubertin G⁵; Burge P⁶; Corbin JF⁷; Gagnon S⁷, Hassiotis A^8
1Optum, Burlington, ON, Canada, ²Optum, Chicago, IL, USA, ³Novartis Pharmaceuticals UK, Surrey, United Kingdom, ⁴Novartis Pharmaceuticals Canada

PSY35 COST-EFFECTIVENESS ANALYSIS OF A VACCINATION PROGRAMME FOR THE PREVENTION OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN ADULTS AGED 50 AND OVER IN GERMANY
Largeron N¹; Préaud E¹; Boehm K²; Aidelsburger P²; Anger D³, Bianic F^3
1Sanofi Pasteur MSD, Lyon, France, ²CAREM GmbH, Sauerlach, Germany, ³Optum, Nanterre, France

Podium Presentations session I: 14:15–15:15

Add to Outlook

CP4: CONCEPTUAL AND PRACTICAL CONSIDERATIONS WHEN DEALING WITH MISSING UTILITY DATA IN LONGITUDINAL TRIALS AND SUBSEQUENT USE IN COST-EFFECTIVENESS ANALYSES
Weston AR¹, Brnabic A¹, Standfield LB^2
1Optum, Sydney, Australia, ²Griffith University, Queensland, Australia

Research podiums session II: 15:30-16:30

Add to Outlook

MD3: DECISION MAKING UNDER UNCERTAINTY:  COVERAGE WITH EVIDENCE DEVELOPMENT IN THE CONTEXT OF MEDICAL DEVICES
Sorenson C¹, Drummond M^2
1London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK, ²University of York, Heslington, UK

Poster session II: 15:30–19:30

Add to Outlook

PCN69 THE COST OF NSCLC IN FRANCE
Martin M¹; Mcguire A²; Marty R³, Lenz C^4
1Optum, Uxbridge, Middlesex, United Kingdom, ²London School of Economics, London, United Kingdom, ³HEVA HEOR, Lyon, France, ⁴Pfizer, Berlin, Germany

PCN120 COST-EFFECTIVENESS OF CABAZITAXEL IN MHRPC IN TURKEY
Yesil A¹; Sahin T¹; De Geer A²; Kim K², Topcu T^1
1Sanofi Turkey, Istanbul, Turkey, ²Optum, Stockholm, Sweden

 

Tuesday, 5 Nov

Poster session III: 8:45–13:45

Add to Outlook

PGI26 COST-EFFECTIVENESS OF EARLY VERSUS DELAYED HEPATITIS C VIRUS (HCV) TREATMENT WITH TELAPREVIR/PEGYLATED INTERFERON ALPHA/RIBAVIRIN TRIPLE THERAPY IN ADULTS AGED 40+ IN FRANCE
Lee A¹; Granados D²; Hulbert E³; McGarry L⁴, Fleischmann J^5
1Optum, Burlington, ON, Canada, ²Janssen France, Issy les Moulineaux, France, ³Optum, Eden Prairie, MN, USA, ⁴Optum, Cambridge, MA, USA, ⁵Janssen EMEA HEMAR, Neuss, Germany

PG128 COST-EFFECTIVENESS OF HEPATITIS C VIRUS (HCV) TREATMENT WITH TELAPREVIR/PEGYLATED INTERFERON ALPHA/RIBAVIRIN TRIPLE THERAPY VERSUS WAITING FOR NEW REGIMENS IN FRANCE
Lee A¹; Granados D²; Hulbert E³; McGarry L⁴, Fleischmann J^5
1Optum, Burlington, ON, Canada, ²Janssen France, Issy les Moulineaux, France, ³Optum, Eden Prairie, MN, USA, ⁴Optum, Cambridge, MA, USA, ⁵Janssen EMEA HEMAR, Neuss, Germany

PSS27 ECONOMIC EVALUATION OF RANIBUZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN CANADA
Lee A¹; Zaour N²; Becker DL¹; Leteneux C³, Barbeau M^2
1Optum, Burlington, ON, Canada, ²Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, ³Novartis Pharma AG, Basel, Switzerland

PSS28 COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT IN TREATING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN SWEDEN
Clements KM¹; Hulbert EM²; Panchmatia HR¹; Eriksson M³; Wittrup-Jensen KU⁴; Nilsson J⁵, Weinstein MC^6
1Optum, Cambridge, MA, USA, ²Optum, Eden Prairie, MN, USA, ³Bayer AB, Solna, Sweden, ⁴Bayer Pharma AG, Berlin, Germany, ⁵Optum, Stockholm, Sweden, ⁶Harvard School of Public Health, Boston, MA, USA

PSS32 A QUEBEC ECONOMIC EVALUATION FOR 36 MONTHS OF RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Haig J¹; Barbeau M²; Ferreira A³, Pickering M^2
1Optum, Burlington, ON, Canada, ²Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, ³Novartis Pharma AG, Basel, Switzerland

Issue panels session II: 13:45–14:45

Add to Outlook

IP9: PHARMACY BENEFIT MANAGEMENT IN THE UNITED STATES: NAUGHTY OR NICE? A COMPARISON OF US AND EUROPEAN DRUG EVALUATION AND COVERAGE POLICIES

Moderator: Scott Ramsey, PhD, MD Member; Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA.

Panelists: Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York and Principal Consultant, Optum, Heslington, York, United Kingdom; Gérard de Pouvourville, PhD, Professor, Department of Health Care Management and Chair, Health Economics Institute, ESSEC Business School, Cergy-Pontoise, France; Brian Solow, MD, Chief Medical Officer, OptumRx, Irvine, CA, USA.

Posters, session IV: 15:00–19:00

Add to Outlook

PCV51 TRENDS IN THE COST-EFFECTIVENESS OF STROKE CARE
Urbina-Valdespino E¹; Saka ö¹; Crichton S²; Rudd A²; Mcguire A³, Wolfe C^2
1Deloitte, Diegem, Belgium, ²King's College London, London, United Kingdom, ³London School of Economics, London, United Kingdom

PCV158 SIMULATING THE POTENTIAL IMPACT OF IMPROVED BLOOD PRESSURE CONTROL ON CLINICAL AND ECONOMIC OUTCOMES IN RUSSIA
Kontsevaya A¹; Alperin P²; Shum K³; Eriksson JA⁴; Vigdorchik A⁵; Shalnova S¹; Boytsov S¹, Hughes D^6
1National Research Center for Preventive Medicine, Moscow, Russia, ²Archimedes, Inc., San Francisco, CA, USA, ³Archimedes Inc., San Francisco, CA, USA, ⁴Optum, Stockholm, Sweden, ⁵Norartis Russia Pharma LLC, Moscow, Russia, ⁶Novartis International AG, Basel, Switzerland

PMH19 ASSOCIATION BETWEEN COGNITIVE FUNCTION AND 3 MONTH HEALTH CARE COSTS AMONG PATIENTS INITIATING AN ANTIDEPRESSANT FOR DEPRESSIVE DISORDER IN AN AMBULATORY CARE SETTING
Kurlander JL¹; Walker V¹; Essoi B¹; Samp J²; Akhras KS², Yang J^2
1Optum, Eden Prairie, IL, USA, ²Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA

PMS8 EQ-5D UTILITY WEIGHTS ASSOCIATED WITH RESPONSE TO TREATMENT WITH MATRIX APPLIED AUTOLOGOUS CULTURED CHONDROCYTES (MACI) IMPLANT AND MICROFRACTURE FOR CARTILAGE DEFECTS OF THE KNEE
Saris D¹; Brittberg M²; Mehin N³; Dehle F⁴; Dowton D⁴; Kili S⁵, Price A^6
1University Medical Center Utrecht, Utrecht, Netherlands, ²Region Halland Orthopaedics, Kungsbacka, Sweden, ³Sanofi Biosurgery, Paris, France, ⁴Optum, Sydney, Australia, ⁵Sanofi Biosurgery, Oxford, United Kingdom, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom

PMS105 THE RESOURCE USE RELATED TO HIP FRACTURES BASED ON DATA FROM ICUROS
Wintzell V¹; Ivergård M¹; Tankó LB²; Barghout V²; Svedbom A¹; Alekna V³; Bianchi ML⁴; Clark P⁵; Díaz Curiel M⁶; Dimai HP7; Jürisson M⁸; Lesnyak O⁹; McCloskey E¹⁰; Sanders KM¹¹; Thomas T¹²; Borgström F¹³, Kanis JA^14
1Optum, Stockholm, Sweden, ²Novartis Pharma AG, Basel, Switzerland, ³Vilnius University, Faculty of Medicine, Vilnius, Lithuania, ⁴Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy, ⁵Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, ⁶Catedra de Enfermedades Metabolicas Óseas, Universidad Autonoma, Madrid, Spain, ⁷Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, ⁸Faculty of Medicine, Tartu University, Tartu, Estonia, ⁹Ural State Medical Academy, Yekaterinburg, Russia, ¹⁰Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom, ¹¹Department of Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, ¹²INSERM U1059, CHU-St-Etienne, Saint Etienne, France, ¹³LIME/MMC, Karolinska Institutet, Stockholm, Sweden, ¹⁴WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom

 

Workshops, session III: 16:15–17:15

Add to Outlook

W15: EVIDENCE-BASED DETERMINISTIC SENSITIVITY ANALYSES: CASE STUDIES USING ISPOR-SMDM GUIDELINES FOR UNCERTAINTY ANALYSES
Discussion Leaders: Anju Parthan, Associate Director, Life Sciences, Optum, Cambridge, MA, USA; Milton C. Weinstein, PhD, Henry J Kaiser Professor of Health Policy & Management, Harvard School of Public Health, Boston, MA, USA; Kelly Fust, MS, Project Manager, Life Sciences, Optum, Cambridge, MA, USA

W17: DO YOU WANT TO HEAR THE BAD NEWS? PATIENT PREFERENCES AND THE DEBATE ON THERAPEUTICALLY UNINFORMATIVE DIAGNOSTIC-TEST INFORMATION
Discussion Leaders: F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Systems and Services Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada; Axel C. Mühlbacher, PhD, Professor for Health Economics and Health Care Management, IGM Institute, Neubrandenburg, Germany.

 

Wednesday, 6 Nov

Posters session IV: 8:45–13:45

Add to Outlook

PRM18 CLASSIFICATION OF COGNITIVE DYSFUNCTION AND COGNITIVE NORMAL USING SCORES FROM FOUR COGNITIVE ASSESSMENTS IN PATIENTS WITH DEPRESSIVE DISORDER
Maruff P¹; Walker V²; Samp J³; Essoi B²; Kurlander JL², Akhras KS^3
1CogState, New Haven, CT, USA, ²Optum, Eden Prairie, MN, USA, ³Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA

PRM26 IMPACT OF USING EITHER MULTIPLICATIVE OR ADDITIVE UTILITY DECREMENTS IN DECISION MODELS
Cure S¹; Despiégel N², Guerra I^1
1Optum, Uxbridge, United Kingdom, ²Optum, Nanterre, France

PRM49 COVERING THE PASS: DEVELOPMENT OF PROTOCOL TEMPLATE LANGUAGE (PTL) FOR DATA COLLECTION AND DATA MANAGEMENT (DM) IN POST-AUTHORIZATION SAFETY STUDIES (PASS)
Oberthur Johnson L¹; Watts H¹; Krishnan S¹; Zarotsky V²; Spannheimer A³; Siebenaler J¹; Gulyas S¹, Clark S^1
1Optum, Eden Prairie, MN, USA, ²Optum, Eden Prairie, MN, USA, ³Optum (Deutschland) GMBH, Munchen, Germany

PRM197 EVALUATING OVERALL SURVIVAL IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES: A METHODOLOGICAL REVIEW AND APPLICATION IN NON-SMALL CELL LUNG CANCER
Jonsson L¹; Fleischer F²; Bluhmki E², Griebsch I^2
1Optum, Stockholm, Sweden, ²Boehringer Ingelheim Pharma GmbH, Ingelheim am Rhein, Germany

PRM203 STRUCTURAL FAILURE TIME MODELING OF OVERALL SURVIVAL EFFECTS IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES
Jonsson L¹; Fleischer F²; Bluhmki E², Griebsch I^2
1Optum, Stockholm, Sweden, ²Boehringer Ingelheim Pharma GmbH, Ingelheim am Rhein, Germany

PUK18 LONG-TERM COSTS AND SURVIVAL ASSOCIATED WITH IMMUNOSUPPRESSANT FOLLOWING LIVER TRANSPLANTATION: A MARKOV MODEL
Bianic F¹; Ricci JF²; Damera V³; Bhattacharyya S⁴, Irish W^5
1Optum, Nanterre, France, ²WELLMERA AG, Basel, France, ³Optum, Uxbridge, United Kingdom, ⁴Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵CTI Clinical Trial and Consulting Services

Workshops session V: 13:45–14:45

Add to Outlook

W26: INCLUSION OF CLINICAL TRIAL DATA AND OTHER EVIDENCE IN CLINICAL PRACTICE GUIDELINES: AN IMPORTANT OPPORTUNITY FOR INDUSTRY
Discussion Leaders: Adele R. Weston, PhD, Executive Vice President & Senior Scientist, Health Economics and Outcomes Research, Optum, Sydney, Australia; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Systems and Services Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.